Sera Prognostics, Inc. (SERA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sera Prognostics, Inc. (SERA) Healthcare & Pipeline Overview

Sera Prognostics, Inc. develops and commercializes biomarker tests, primarily the PreTRM test, to predict preterm birth risk in asymptomatic pregnancies. The company focuses on improving maternal and neonatal health outcomes within the women's health diagnostics sector, addressing a critical need for early risk assessment and intervention.

What Is the Investment Thesis for SERA?

Sera Prognostics operates in the high-growth area of women's health diagnostics, with its PreTRM test addressing a critical need for preterm birth risk prediction. The company's focus on expanding its product pipeline to include diagnostics for preeclampsia, gestational diabetes, and other pregnancy-related conditions presents significant growth opportunities. However, the company's current financial performance, characterized by a negative profit margin of -56386.0% and a negative gross margin of -191.2%, raises concerns about its path to profitability. Successful commercialization of its product pipeline and strategic partnerships with healthcare providers and payers are crucial for Sera Prognostics to achieve sustainable growth. Investors should closely monitor the company's revenue growth, cost management, and progress in securing reimbursement coverage for its diagnostic tests.

Based on FMP financials and quantitative analysis

SERA Key Highlights

Market capitalization of $78.3M, reflecting its position as a smaller player in the diagnostics market.

• Negative profit margin of -56386.0%, indicating significant challenges in achieving profitability.
• Negative gross margin of -191.2%, suggesting high costs associated with its diagnostic tests.
• Beta of 1.06, indicating a slightly higher volatility compared to the overall market.
• No dividend yield, as the company is currently focused on reinvesting earnings for growth.

Who Are SERA's Competitors?

SERA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SERA's Key Strengths?

Proprietary PreTRM test for preterm birth risk prediction.

• Focus on women's health diagnostics.
• Developing a portfolio of diagnostic tests.
• Experienced management team.

What Are SERA's Weaknesses?

Negative profit and gross margins.

• Limited commercialization experience.
• Dependence on a single product (PreTRM).
• Requires significant capital investment for R&D and commercialization.

What Could Drive SERA Stock Higher?

Publication of clinical studies validating the performance of the PreTRM test.

• Expansion of commercial partnerships with healthcare providers and payers.
• Regulatory approvals for new diagnostic tests in the pipeline.
• Progress in securing reimbursement coverage for diagnostic tests.

What Are the Key Risks for SERA?

Financial-distress signal — its Altman Z-Score of -4.56 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-46.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established diagnostic companies.
• Regulatory hurdles and reimbursement challenges.
• Technological obsolescence.
• Economic downturn affecting healthcare spending.
• Dependence on the PreTRM test for revenue.

What Are the Growth Opportunities for SERA?

• Expansion of PreTRM test utilization: Increasing the adoption of the PreTRM test among healthcare providers and pregnant women represents a significant growth opportunity. This can be achieved through targeted marketing campaigns, clinical education programs, and partnerships with key opinion leaders. The market for preterm birth prediction is estimated to be substantial, with approximately 10% of pregnancies resulting in preterm birth. Successful penetration of this market could drive significant revenue growth for Sera Prognostics.
• Development and commercialization of new diagnostic tests: Sera Prognostics is developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, gestational diabetes, and postpartum depression. Successful development and commercialization of these tests would expand the company's addressable market and diversify its revenue streams. The market for diagnostics in these areas is substantial, with significant unmet needs for accurate and timely risk assessment.
• Geographic expansion: Expanding into new geographic markets, both domestically and internationally, represents another growth opportunity for Sera Prognostics. This can be achieved through strategic partnerships with local distributors and healthcare providers. The global market for women's health diagnostics is growing, driven by factors such as increasing access to healthcare and rising awareness of the importance of prenatal care.
• Strategic partnerships and collaborations: Forming strategic partnerships with pharmaceutical companies, healthcare providers, and research institutions can accelerate the development and commercialization of Sera Prognostics' diagnostic tests. These partnerships can provide access to funding, expertise, and distribution channels. Collaboration with pharmaceutical companies could lead to the development of companion diagnostics that personalize treatment decisions for pregnant women.
• Securing reimbursement coverage: Obtaining favorable reimbursement coverage from government and private payers is crucial for the widespread adoption of Sera Prognostics' diagnostic tests. This requires demonstrating the clinical utility and cost-effectiveness of the tests. The company needs to actively engage with payers to negotiate favorable reimbursement rates and ensure access to its diagnostic tests for pregnant women.

What Are SERA's Competitive Advantages?

• Proprietary biomarker technology for predicting preterm birth risk.
• Focus on addressing unmet needs in women's health diagnostics.
• Established relationships with key opinion leaders in obstetrics.
• Developing a portfolio of diagnostic tests for various pregnancy-related conditions.

What Does SERA Do?

Sera Prognostics, Inc., founded in 2008 and headquartered in Salt Lake City, Utah, is a women's health diagnostic company dedicated to discovering, developing, and commercializing innovative biomarker tests. The company's core focus is on improving pregnancy outcomes, particularly by predicting the risk of spontaneous preterm birth. Their flagship product, the PreTRM test, is a blood-based biomarker test designed to identify asymptomatic singleton pregnancies at risk of preterm birth. This allows for proactive intervention and improved care for both mother and child. Beyond PreTRM, Sera Prognostics is actively developing a portfolio of product candidates targeting various pregnancy-related conditions. These include preeclampsia, molecular time-to-birth assessment, gestational diabetes mellitus, fetal growth restriction, stillbirth risk assessment, and postpartum depression prediction. The company aims to provide comprehensive diagnostic solutions throughout the entire pregnancy journey, from early risk assessment to postpartum care. Sera Prognostics operates primarily in the United States, focusing on establishing partnerships with healthcare providers and payers to integrate its diagnostic tests into standard prenatal care protocols. The company's competitive advantage lies in its proprietary biomarker technology and its focus on addressing unmet needs in women's health diagnostics.

What Products and Services Does SERA Offer?

• Develop blood-based biomarker tests for women's health.
• Focus on improving pregnancy outcomes through early risk assessment.
• Offer the PreTRM test to predict the risk of spontaneous preterm birth.
• Develop diagnostic tests for preeclampsia, gestational diabetes, and other pregnancy-related conditions.
• Commercialize diagnostic tests through partnerships with healthcare providers.
• Aim to integrate diagnostic tests into standard prenatal care protocols.

How Does SERA Make Money?

• Develop and commercialize proprietary biomarker tests.
• Generate revenue through sales of the PreTRM test and future diagnostic products.
• Partner with healthcare providers and payers to integrate tests into clinical practice.
• Focus on securing reimbursement coverage for diagnostic tests.

What Industry Does SERA Operate In?

Sera Prognostics operates within the medical diagnostics and research industry, specifically focusing on women's health. The industry is characterized by increasing demand for advanced diagnostic tools that can improve patient outcomes and reduce healthcare costs. The market for prenatal and perinatal diagnostics is experiencing growth, driven by factors such as rising maternal age, increasing prevalence of pregnancy-related complications, and growing awareness of the importance of early risk assessment. Sera Prognostics competes with established diagnostic companies and specialized women's health companies. Success in this market requires strong clinical validation, regulatory approvals, and effective commercialization strategies.

Who Are SERA's Key Customers?

• Pregnant women at risk of preterm birth.
• Obstetricians and other healthcare providers who provide prenatal care.
• Hospitals and clinics that offer prenatal diagnostic services.
• Payers, including insurance companies and government healthcare programs.

Over the past six months, Sera Prognostics, Inc. insiders filed 41 SEC Form 4 transactions — 9 sales and 32 purchases. On net that is roughly 717K shares acquired (about $821K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Sera Prognostics, Inc.

Revenue for Sera Prognostics, Inc. came in at $30K during Q2 FY2026, a 114.3% improvement versus the preceding quarter. The company recorded a net loss of $9.1M, with diluted EPS of $-0.18. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, SERA averaged $-0.17 in diluted EPS.

SERA Valuation & Market Position

With a $78.3M market cap, Sera Prognostics, Inc. sits in the micro-cap segment of the market. Analyst price targets span from $6.00 to $6.00, with a consensus of $6.00. At the current price of $2.05, that implies approximately 193% upside potential. Relative to its peer group, SERA's quantitative score of 18/100 is below the peer average of 42/100.

Return on equity for Sera Prognostics, Inc. stands at -46.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -38.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -36.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -32.9%, the inverse of the P/E and a quick read on earnings relative to price.

Sera Prognostics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.56 places it in the distress zone, a signal of elevated financial risk.

Sera Prognostics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.7% above estimates on average.

Company Profile

Sera Prognostics, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Zhenya Lindgardt. SERA has traded publicly since 2021.

SERA Financials

SERA Latest News

SERA Analyst Consensus

SERA MoonshotScore

What Investors Ask About Sera Prognostics, Inc. (SERA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources